UK open data stance: bold or brash?

Share this article:

A UK proposal to make anonymous patient data available for pharma company research elicited cheers and jeers.

Part of a package of reforms unveiled by prime minister David Cameron last month, the proposal was intended to integrate medical research more closely with the NHS and biopharma.

Such drugmakers as Glaxo­SmithKline, as well as academics, hailed Cameron's plan. With privacy safeguards, “access to real data on patient treatment…could help to cut drug development costs and spur rapid innovation,” wrote the Financial Times in an op-ed.

However, medical societies and others warned that data could still include age profiles and post codes, which can be used to trace identities. “We are concerned that elements of the government's proposals could, if implemented, undermine patient confidentiality,” said the British Medical Association in a statement.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"